In the high-grade ovarian serous carcinoma subgroup, 31.4% of cases harbored a clinically significant mutation (n = 61 cases, 47 BRCA1 and n = 14 BRCA2), whereas only one likely pathogenic BRCA2 alteration was detected in non-high-grade serous carcinoma. This evidence concerns the gene BRCA1 and serous adenocarcinoma.